Description
Created On: 2020-07-15
Record Count: 9
Primary Industries
- Drugs
- Cancer
- Therapeutic
- Disease
- Weight Loss
- Food
- Medical
- Diagnostic
- HIV / AIDs
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 286016
US Patent #5,200,553 – Biologically active carboxylic acid esters
Licensed Product(s) shall mean: Any product which is covered in whole or in part by a valid and unexpired claim contained in the Patent Rights in the country in which the product is made, used, leased, or sold; Any product which is manufactured by using a process which is covered in whole or in part by a valid and unexpired claim contained in the Patent Rights in the country in which the process is used; Any product which is used according to a method which is covered in whole or in part by a valid and unexpired claim contained in the Patent Rights in the country in which the method is used.
Licensed Process(es) shall mean any process or method, which is covered, in whole or in part, by a valid and unexpired claim contained in the Patent Rights in the country in which the process or method is used.
IPSCIO Record ID: 169272
Licensee at its own expense and utilizing patent counsel of its choice shall have the sole right and responsibility for the prosecution and maintenance of the Nudelman Patent, provided that Licensee shall not take any action with respect to the Nudelman Patent that could result in any diminution of rights relating to the composition of matter claims relating to AN10. Licensor shall have the sole right and responsibility for the prosecution and maintenance of the Hemoglobinopathies Patent.
Hemoglobinopathies Patent shall mean issued U.S. Patent No. 5,569,675 and any related foreign patent applications or patents, including any continuations, continuations-in-part, divisional, reissues, reexaminations or extensions thereof.
Nudelman Patent shall mean issued U.S. Patent No. 5,200,553 and any related foreign patent applications or patents, including any continuations, continuations-in-part, divisional, reissues, reexaminations or extensions thereof.
AN 10 shall mean butylidene dibutyrate.
IPSCIO Record ID: 230821
* Is covered in whole or in part by an issued, unexpired claim or a pending claim contained in the Patent Rights in the country in which any Licensed Product is made, used, or sold;
* Is manufactured by using a process which is covered in whole or in part by an issued, unexpired claim or a pending claim contained in the Patent Rights in the country in which any Licensed Process is used or in which the Licensed Product is used or sold.
A Licensed Process shall mean any process with application solely in the Non-Thalidomide Field and which is covered in whole or in part by an issued, unexpired claim or a pending claim contained in the Patent Rights.
Thalidomide may have use in treating diseases fed by the growth of tiny blood vessels – a growth process known as angiogenesis.
Licensee licensed the use of Thalidomide for cancer and other antiangiogenic mediated diseases from Licensor, and conducted four Phase II clinical trials and secured two orphan drug indications for the use of thalidomide in certain cancers.
IPSCIO Record ID: 273410
US Patent Application SN 10/440,404, entitled, 'Method for Treating Obesity' and filed May 19, 2003. (Atising from Licensor Office of Science and Technology File #2081)
PCT Patent Application PCT/US03/15703, entitled, 'Method of Treating Obesity and filed May 19, 2003. (Arising from Licensor Office of Science and Technology File #2081)
US Provisional Patent Application SN 60/535,799, entitled, 'Method of Reducing Weight Gain Risk Associated with Antidepressant Therapy' and filed January 13, 2004. (Arising from Licensor Office of Science and Technology File# 2308)
US Provisional Patent Application SN 60/535,800, entitled Method of Reducing Weight Gain Risk Associated with Antipsychotic Therapy' and filed January 13, 2004. (Arising from Licensor Office of Science and Technology File #2294)
Licensed Product shall mean any product or part thereof which:
(a)
is covered in whole or in part by any valid claim contained in the Licensor Patent Rights in the country in which any such product or part thereof is made, used or sold; and/or
(b)
is manufactured by using a process or is employed to practice a process which is covered in whole or in part by a valid claim contained in the Licensor Patent Rights in the country in which any Licensor Licensed Process is used or in which such product or part thereof is used or sold; and/or
c)
in its intended use, practices, incorporates, or otherwise utilizes, in whole, or in part, a valid claim contained in the Licensor Patent Rights in the country in which any such product or part thereof is made, used, or sold.
Licensed Process shall mean any process which is covered in whole or in part by a valid claim contained in the Licensor Patent Rights.
Licensed Service shall mean any service provided by Licensee (and/or sublicensees, as the case may be) to a third party which utilizes Licensor Licensed Products and/or Licensor Licensed Processes.
IPSCIO Record ID: 282830
Licensed Product shall mean any product which (a) is covered by a valid and unexpired claim contained in a Patent Rights Patent in the country in which such Licensed Product is made, used or sold; or (b) is covered by a claim which is contained in a pending Patent Rights Patent Application in the country in which such Licensed Product is made, used or sold.
Patent Rights shall mean (a) United States Patent 4,808,425, issued February 28, 1989, entitled 'Method for the Ultrapasteurization of Liquid Whole Egg Products'; (b) United States Patent 4,957,759, issued September 18, 1990, entitled 'Ultra-Pasteurization of Liquid Whole Egg Products'; (c) United States Patent 4,994,291 issued February 19, 1991 entitled 'Method for Pasteurizing Liquid Whole Egg Products'; (d) United States Patent 5,019,408 issued May 28, 1991, entitled 'Method for Pasteurizing Liquid Whole Egg Products'; and (e) United States Patent 4.957,760 issued September 18, 1990 entitled 'Ultrapasteurization of Liquid Whole Egg Products by Direct Heat' and any continuations, divisions, reissues, reexaminations and extensions thereof (collectively 'Patent Rights Patents'); and all existing and later-filed U.S. or foreign patent applications corresponding to or claiming priority benefit of any of the foregoing, and any continuations, divisions, reissues, reexaminations and extensions thereof including without limitation the currently pending reissue application of United States Patent 5,019,408 which includes the product claim referred to in Section 1.4 (collectively 'Patent Rights Patent Applications').
Licensed Process shall mean any process which (a) is covered by a valid and unexpired claim contained in a Patent Rights Patent in the country in which such Licensed Process is used or practiced; or (b) is covered by a claim which is contained in a pending Patent Rights Patent Application in the country in which such Licensed Process is used or practiced.
IPSCIO Record ID: 203485
Licensor agrees that it shall not grant any other license to make, have made, use, lease and sell Licensed Products or to utilize Licensed Processes in the Research or In Vitro Diagnostics fields and in the In Vivo Diagnostics field and the Therapeutics field of use during the period.
At the end of the exclusivity period, the Licensee may extend the exclusivity or the rights will change to non-exclusive for the remainder of the term of the agreement.
Licensor agrees that its grant to Licensee to use of the Tangible Property for commercial purposes shall be exclusive in perpetuity unless this Agreement is terminated prior to the last to expire of the Patent Rights.
The Tangible Property shall mean any or all of the hybridorna cell lines from the Licensors laboratory with the designation(s) MCF-7 Bl through B9.
A Licensed Product shall mean any product or part thereof which:
(a) is covered in whole or in part by a pending claim contained in a Patent Rights Patent Application in the country in which any Licensed Product is made, used or sold; or, a valid and unexpired claim contained in a Patent Rights Patent in the country in which any Licensed Product is made, used or sold; or
(b) is manufactured using a process which is covered in whole or in part by a pending claim contained in a Patent Rights Patent Application in the country in which any Licensed Process is used, or, a valid or unexpired claim contained in a Patent Rights Patent in the country in which any Licensed Process is used; or,
(c) is developed or manufactured using the Tangible Property.
A Licensed Process shall mean any process for making Licensed Products which is covered in whole or in part by:
(a) a pending claim contained in a Patent Rights Patent Application; or
(b) a valid and unexpired claim contained in a Patent Rights Patent; or which
(c) uses the Tangible Property.
The Licensee develops, produces and distributes products for the diagnosis and potential treatment of cancer based on its proprietary nuclear matrix protein technology.
IPSCIO Record ID: 273408
US Patent Application SN 10/440,404, entitled, 'Method for Treating Obesity' and filed May 19, 2003. (Atising from Licensor Office of Science and Technology File #2081)
PCT Patent Application PCT/US03/15703, entitled, 'Method of Treating Obesity and filed May 19, 2003. (Arising from Licensor Office of Science and Technology File #2081) US Provisional Patent Application SN 60/535,799, entitled, 'Method of Reducing Weight Gain Risk Associated with Antidepressant Therapy' and filed January 13, 2004. (Arising from Licensor Office of Science and Technology File# 2308)
US Provisional Patent Application SN 60/535,800, entitled Method of Reducing Weight Gain Risk Associated with Antipsychotic Therapy' and filed January 13, 2004. (Arising from Licensor Office of Science and Technology File #2294)
Licensed Product shall mean any product or part thereof which: (a)
is covered in whole or in part by any valid claim contained in the Licensor Patent Rights in the country in which any such product or part thereof is made, used or sold; and/or (b) is manufactured by using a process or is employed to practice a process which is covered in whole or in part by a valid claim contained in the Licensor Patent Rights in the country in which any Licensor Licensed Process is used or in which such product or part thereof is used or sold; and/or c)
in its intended use, practices, incorporates, or otherwise utilizes, in whole, or in part, a valid claim contained in the Licensor Patent Rights in the country in which any such product or part thereof is made, used, or sold.
Licensed Process shall mean any process which is covered in whole or in part by a valid claim contained in the Licensor Patent Rights.
Licensed Service shall mean any service provided by Licensee (and/or sublicensees, as the case may be) to a third party which utilizes Licensor Licensed Products and/or Licensor Licensed Processes.
IPSCIO Record ID: 230759
A Licensed Process is any process which is covered in whole or in part by an issued, unexpired claim or a pending claim contained in the Patent Rights; or, Patent Rights; or, is derived from Patent Rights or know-how, and related to or described in is sold, manufactured or used in any country under this Agreement.
A Licensed Product shall mean any product or part thereof which is covered in whole or in part by an issued, unexpired claim or a pending claim contained in the Patent Rights in the country in which any Licensed Products are made, used or sold; or, is manufactured by using a process which is covered in whole or in part by an issued, unexpired claim or a pending claim contained in the Patent Rights in the country in which any Licensed Process is used or in which such product or part thereof is used or sold; or,
is derived from Patent Rights or know-how, and related to or described in Patent Rights.
(a) Human [blood] disorders, [metabolic and congenital]. This field includes human [hematological] diseases that arise due to the absence, over-expression or altered expression of proteins normally (present in blood]. The primary site and location of these proteins is [blood]. Specifically included are human [hemoglobinopathies (i. e. Sickle Cell Anemia and Thalassemia)] and human disorders of the [coagulation metabolism (i.e., Hemophilia A (factor VIII), Von Willebrands Disease (factor VIII) and Hemophilia B (factor IX))]. Specifically excluded are human [neoplasias of the lymphoreticular system (lymphomas, reticuloendothelioses, or plasma cell dyscrasias)].
(b) Human [malignant neoplastic] diseases. This field includes all forms of human (cancer, including but not limited to skin cancers and all solid tumors]. This field also includes all forms of human [cancers of the hematopoietic tissues (the leukemias), Hodgkins Disease and Non-Hodgkins Lymphoma].
c) relating to a syndrome (AIDS) characterized by opportunistic infections occuring as a result of profound
deficiency of the helper – T4 lymphocytes (CD4 lymphocytes). At any time during the life of this Agreement the definition of AIDs shall be that definition currently in use by the Centers for Disease Control, Atlanta, Georgia].
(d) All human [infectious diseases other than HIV]. This Field includes: [human viral diseases (besides HIVs, human bacterial, yeast and other microorganism based diseases, and all other human infectious diseases.
IPSCIO Record ID: 279311
(a) publish the general scientific findings from research related to Licensed Subject Matter, subject to the terms of Article XI-Confidential Information and Publication; and
(b) use Licensed Subject matter solely for its own internal, non-commercial research, teaching, and other educationally-related purposes; and
(c) request that the Licensee transfer Licensed Subject Matter to academic or research institutions for non-commercial research use or for purposes of collaboration upon terms reasonably acceptable to the Licensee and such third party; provided, however, that Licensee will not unreasonably withhold consent to University’s use of the Licensed Subject Matter in collaborations between University, and/or the National Cancer Institute (NCI).
Patent Rights means University’s rights in information or discoveries described in invention disclosures below or in the subsequent reductions to practice of such information or discoveries (so long as such subsequent reductions to practice are not obligated to a third party), or claimed in any patents, and/or patent applications, whether domestic or foreign, based on such invention disclosures and such reductions to practice (that are not obligated to a third party) and all domestic and foreign divisionals, continuations, continuations-in-part, reissues, reexaminations or extensions thereof, including any foreign counterparts thereto and any letters patent that issue thereon, including but not limited to: (a) Provisional Application entitled, “Compounds and Methods for the Treatment of Cancer†filed July 16, 2004; (b) U.S. Application Serial Number 60/346,492 filed January 7, 2002; (c) WO 2003/057012 filed January 7, 2003; (d) U.S. Application Serial Number 10/337,969 filed January 7, 2003; and (e) national stage filings for MDA01-063 in Europe, Japan, Canada and Australia.
MDA01-063 “New Organic Arsenic Derivatives as a Treatment for Cancer,†Srdan Verstovsek, M.D., Ph.D., Ralph A. Zingaro Ph.D., Emil J. Freireich, M.D., Hatice Duzkale, M.D., Hagop M. Kantarjian, M.D.
MDA04-076 “Arsenic-Lipid Derivatives as a Treatment for Cancer,†Srdan Verstovsek, M.D., Ph.D., Ralph A. Zingaro Ph.D., Hagop M. Kantarjian, M.D., M. Gao
Licensed Products means any product or service that is covered in whole or in part by a valid claim contained in the Patent Rights in the country in which the product is made, used, leased or sold.
ZIO-101 is an organic arsenic compound covered by an issued U.S. patent and applications internationally. A form of commercially available inorganic arsenic (arsenic trioxide (Trisenox®) or ATO) has been approved for the treatment of acute promyelocytic leukemia (APL), a precancerous condition, and is on the compendia listing for the therapy of multiple myeloma as well as having been studied for the treatment of various other cancers.
